NCT07244926

Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer

Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in Second-line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Without Actionable Gene Alterations: a Single-arm, Phase II Trial

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 31 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this single-arm, phase II study, we aimed to evaluate the efficacy and safety of sac-TMT plus bevacizumab in patients with advanced non-squamous NSCLC who showed disease progression on or after first-line ICI plus platinum-based chemotherapy.

Conditions

• Lung Cancer

Interventions

Type	Name	Description
DRUG	Sacituzumab tirumotecan plus bevacizumab	The eligible patients will receive intravenous sac-TMT 4mg/kg every 2 weeks plus intravenous bevacizumab 10mg/kg every 2 weeks until disease progression, death, unacceptable toxicity, or another treatment discontinuation criterion is met.

Timeline

• Start date: 2025-12-01
• Primary completion: 2027-06-01
• Completion: 2028-06-01
• First posted: 2025-11-24
• Last updated: 2025-11-24

Locations

1 site across 1 country: China